Revium Rx (RVRC) Cash & Equivalents (2024 - 2026)

Revium Rx has disclosed Cash & Equivalents across 3 years of filings, most recently posting $842000.0 for Q2 2026.

• In Q2 2026, Cash & Equivalents changed N/A year-over-year to $842000.0; the TTM figure through Jun 2026 stood at $842000.0 (changed N/A YoY), while the FY2025 annual figure was $1.7 million, down 48.65% from the prior year.
• Cash & Equivalents came in at $842000.0 for Q2 2026 at Revium Rx, down from $1.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $3.3 million in Q4 2024 to a low of $842000.0 in Q2 2026.
• Average Cash & Equivalents over 3 years is $1.9 million, with a median of $1.7 million recorded in 2025.
• The largest YoY upside for Cash & Equivalents was 48.65% in 2025 against a maximum downside of 48.65% in 2025.
• Over 3 years, Cash & Equivalents stood at $3.3 million in 2024, then slumped by 48.65% to $1.7 million in 2025, then plunged by 49.82% to $842000.0 in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $842000.0 in Q2 2026, $1.7 million in Q4 2025, and $3.3 million in Q4 2024.